Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.55 |
| ▸ | KDR | P35968 | 3/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.44 |
| ▸ | PRKACA | P17612 | 2/20 | 0.44 |
| ▸ | CDK8 | P49336 | 2/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.44 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3537661 | 0.98 | CYP11B2 (0.54) | CYP11B2KDRMAP4K4PRKACACDK8 | |
| SCHEMBL10652058 | 0.84 | CYP11B2 (0.50) | CYP11B2IDO1CYP11B1SRCTBXAS1 | |
| SCHEMBL3540598 | 0.83 | CYP11B2 (0.65) | CYP11B2KDRMAP4K4PRKACACDK8 | |
| SCHEMBL2353570 | 0.82 | SRC (0.49) | CYP11B2CHEK1IDO1SRCTBXAS1 | |
| SCHEMBL2349590 | 0.81 | CYP11B2 (0.48) | CYP11B2IDO1TBXAS1ALDH1A1PTGS1 | |
| Hydrochloric Acid SCHEMBL3535788 | 0.81 | CYP11B2 (0.63) | CYP11B2KDRMAP4K4PRKACACDK8 | |
| Hydrochloric Acid SCHEMBL9265699 | 0.81 | SRC (0.48) | CYP11B2CHEK1IDO1SRCTBXAS1 | |
| SCHEMBL2350354 | 0.80 | CYP11B2 (0.47) | CYP11B2FYNCHEK1IDO1TBXAS1 | |
| SCHEMBL2353759 | 0.80 | IDO1 (0.52) | CYP11B2IDO1CYP11B1SRCTBXAS1 | |
| Hydrochloric Acid SCHEMBL9265008 | 0.79 | IDO1 (0.51) | CYP11B2IDO1CYP11B1SRCTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713991-B2 | Imidazo[[1, 5-A] pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2010-05-11 | — | — | US | claimed |
| EP-1565463-B1 | IMIDAZO[1,5A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2008-06-11 | — | — | EP | claimed |
| US-20070197582-A1 | IMIDAZO[[1, 5-A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2007-08-23 | — | — | US | claimed |
| US-7223866-B2 | Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2007-05-29 | — | — | US | claimed |
| US-20060058342-A1 | Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2006-03-16 | — | — | US | claimed |
| JP-2006508970-A | — | — | 2006-03-16 | — | — | JP | claimed |
| EP-1565463-A1 | IMIDAZO[1,5A]PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | Novartis AG (CH) | 2005-08-24 | — | — | EP | claimed |
| WO-2004046145-A1 | IMIDAZO[1, 5A]PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2004-06-03 | — | — | WO | claimed |
| US-7713991-B2 | Imidazo[[1, 5-A] pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2010-05-11 | — | — | US | disclosed |
| US-7713991-B2 | Imidazo[[1, 5-A] pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2010-05-11 | — | — | US | disclosed |
| US-7713991-B2 | Imidazo[[1, 5-A] pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2010-05-11 | — | — | US | disclosed |
| EP-1565463-B1 | IMIDAZO[1,5A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2008-06-11 | — | — | EP | disclosed |
| EP-1565463-B1 | IMIDAZO[1,5A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2008-06-11 | — | — | EP | disclosed |
| US-20070197582-A1 | IMIDAZO[[1, 5-A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2007-08-23 | — | — | US | disclosed |
| US-7223866-B2 | Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2007-05-29 | — | — | US | disclosed |
| US-7223866-B2 | Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2007-05-29 | — | — | US | disclosed |
| US-20060058342-A1 | Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2006-03-16 | — | — | US | disclosed |
| EP-1565463-A1 | IMIDAZO[1,5A]PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | Novartis AG (CH) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004046145-A1 | IMIDAZO[1, 5A]PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2004-06-03 | — | — | WO | disclosed |
| WO-2004046145-A1 | IMIDAZO[1, 5A]PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058342-A1 | Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases | CYP11B1, CYP17A1, CYP27A1 | CYP11B2 8/4885KDR 568/4885MAP4K4 282/4885 |
| US-20070197582-A1 | IMIDAZO[[1, 5-A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | CYP11B1, CYP27A1, CYP17A1 | CYP11B2 7/4885KDR 745/4885MAP4K4 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.